{
  "docId": "019de075-b6c3-715f-bed8-4c3a534b1fd4",
  "docSlug": "88f1b85a63c225232d32e053da178119",
  "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 25 slides",
  "authorId": "mainz-biomed-nv",
  "authorName": "Mainz Biomed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 25,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes a citation of a study from the Université de Sherbrooke published in 'cancers'.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-b6c3-715f-bed8-4c3a534b1fd4/15",
  "deckHref": "/decks/019de075-b6c3-715f-bed8-4c3a534b1fd4",
  "deckJsonHref": "/decks/019de075-b6c3-715f-bed8-4c3a534b1fd4.json",
  "deckAnchorHref": "/decks/019de075-b6c3-715f-bed8-4c3a534b1fd4#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.54,
        "x": 0.39,
        "y": 0.415
      },
      "kind": "callout",
      "text": "A panel of mRNA targets was tested on stool samples obtained from 102 patients including 78 CRC stage I-III and 24 AA as well as 32 healthy controls",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "001e02ff-77ba-4f7d-8370-7de720063b80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.3,
        "x": 0.1,
        "y": 0.46
      },
      "kind": "image",
      "text": "UDS Université de Sherbrooke",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab6fcc32-d502-45ce-848b-c4bb6895bd21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.37,
        "x": 0.035,
        "y": 0.615
      },
      "kind": "image",
      "text": "Multitarget Stool mRNA Test for Detecting Colorectal Cancer Lesions Including Advanced Adenomas",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1decafe9-d594-4d54-b410-9c694ab41cfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.54,
        "x": 0.39,
        "y": 0.71
      },
      "kind": "list",
      "text": "5 mRNA markers resulted in a 75% sensitivity at > 95% specificity\nFIT did not add to the AA sensitivity but increased the CRC sensitivity\nRNA stability validated by Mainz Biomed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b2d1870-5391-426a-95af-da8942bddf36",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "Potential for Next Gen test to emerge as the most robust and accurate at-home screening test for colorectal cancer\nBiomarkers have demonstrated unique ability to identify curable precancerous colonic polyps as well as curable early-stage colorectal cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b64c6198-87a5-48ac-8c16-805362f48714",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.54,
        "x": 0.39,
        "y": 0.52
      },
      "kind": "table",
      "text": "mRNA only: 75% (AA), 89% (CRC), >95% (Spec); mRNA & FIT: 75% (AA), 95% (CRC), >95% (Spec)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "818594cb-6977-4003-bb39-e4a7d28be16f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Mainz Biomed Acquired Exclusive Rights to Novel mRNA Biomarkers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea35f69c-b8bd-4ae2-a392-dff760d9d405",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "cd8f0c83-23ce-45df-83be-7bd9c9168fc0",
      "evidence": "list/bullet: Potential for Next Gen test to emerge as the most robust and accurate at-home screening test for colorectal cancer",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 25,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "82aba536-6cfb-4714-9432-b52a39ec7273",
      "evidence": "WHY (CRC need), HOW (innovative tests), WHAT (investment ask)",
      "position": 1,
      "objective": "Presenting a compelling investment opportunity",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}